betamethasone-17,21-dipropionate has been researched along with calcitriol in 179 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.56) | 18.2507 |
| 2000's | 50 (27.93) | 29.6817 |
| 2010's | 82 (45.81) | 24.3611 |
| 2020's | 46 (25.70) | 2.80 |
| Authors | Studies |
|---|---|
| Scarpa, C | 1 |
| Hecker, D; Lebwohl, M; Worsley, J; Yueh, G | 1 |
| Pandey, SS; Reddy, DC; Singh, S | 1 |
| van de Kerkhof, PC; van Erp, PE; van Rossum, MM | 1 |
| Bibby, AJ; Buckley, C; Decroix, J; Douglas, WS; Gulliver, W; Iglesias, L; Krogstad, AL; Larsen, FG; Mrowietz, U; Ortonne, JP; Poulin, Y | 1 |
| Bibby, AJ; Bissonnette, R; Cambazard, F; Chu, AC; Decroix, J; Douglas, WS; Kaufmann, R; Lowson, D; Mascaro, JM; Murphy, GM; Stymne, B | 1 |
| Boyden, B; Burg, G; Chu, A; Guenther, L; Guilhou, JJ; Hanssen, LI; Harvima, RJ; Kaufmann, R; Larsen, FG; Papp, KA; Rogers, S; Talbot, D; Tegner, E; van de Kerkhof, PC | 1 |
| Camarasa, JM; Dubertret, L; Ortonne, JP | 1 |
| Hughes-Formella, BJ; Traulsen, J | 1 |
| Lui, H; Shapiro, J | 1 |
| Guenther, LC | 2 |
| Estebaranz, JL; Fleming, C; Hanssen, LI; Kragballe, K; Lui, H; Noerrelund, KL; Ortonne, JP; Persson, LM; Uurasmaa, T; Wozel, G | 1 |
| Traulsen, J | 1 |
| van de Kerkhof, PC | 2 |
| Goodfield, M; Kaufmann, R; Lecha, M; Ortonne, JP | 1 |
| Didriksen, E; Hansen, J; Høy, G; Melchior, N; Persson, J; Simonsen, L | 1 |
| Fenton, C; Plosker, GL | 1 |
| Cambazard, F; Kragballe, K; Murray, S; van de Kerkhof, PC; Wasel, N | 1 |
| Guignard, E; Ortonne, JP; Peeters, P; Sitbon, R | 1 |
| Delvoye, P; Flagothier, C; Henry, F; Piérard, GE; Piérard-Franchimont, C | 1 |
| Chrysomallis, F; Kastanis, A; Lazaridou, E; Loannides, D; Vakirlis, E | 1 |
| Kragballe, K; van de Kerkhof, PC | 1 |
| Kaur, I; Kumar, B; Kumaran, MS | 1 |
| Charakida, A; Charakida, M; Chu, AC; Dadzie, O; Evangelou, G; Teixeira, F | 1 |
| Downs, AM | 1 |
| Flagothier, C; Henry, F; Piérard, GE; Piérard-Franchimont, C | 1 |
| Austad, J; Barnes, L; Bibby, A; Cambazard, F; de la Brassinne, M; Fleming, C; Heikkilä, H; Jolliffe, D; Kragballe, K; Peyri, J; Svensson, A; Toole, J; Wozel, G | 1 |
| Bibby, A; Cambazard, F; Foster, R; Haverkamp, C; Martinez Escribano, JA; Naeyaert, JM; Thaçi, D; Vender, R; White, S | 1 |
| Adriaans, B; Fergusson-Wood, LA; Griffiths, MR; Porter, W | 1 |
| Anstey, AV; Kragballe, K | 1 |
| Austad, J; Barnes, L; Bibby, A; Cambazard, F; de la Brassinne, M; Fleming, C; Heikkilä, H; Kragballe, K; Peyri Rey, J; Svensson, A; Toole, J; Williams, Z; Wozel, G | 1 |
| Bellino, M; Cassano, N; Coviello, C; Loconsole, F; Miracapillo, A; Vena, GA | 1 |
| Cassano, N; Vena, GA | 1 |
| Kragballe, K; Mrowietz, U; Segaert, S; van de Kerkhof, PC | 1 |
| Bovenschen, HJ; Erceg, A; Seyger, MM; Van De Kerkhof, PC; Van Vlijmen-Willems, I | 1 |
| Lebwohl, MG | 1 |
| Dytoc, MT; Kossintseva, I; Ting, PT | 1 |
| Auland, ME; Bottomley, JM; Boyd, G; Douglas, WS; Morais, J | 1 |
| Buckley, C; Cambazard, F; Hoffmann, V; Milsgaard, M; Saari, S; Shapiro, J | 1 |
| Chen, CY; Chen, YH; Lo, PY; Tzung, TY; Yang, CY | 1 |
| Austad, J; Berne, B; Burden, AD; de Unamuno, P; Figueiredo, A; Ganslandt, C; Jemec, GB; Ortonne, JP; Poulin, Y | 1 |
| Bourcier, M; Cambazard, F; Clonier, F; Gupta, G; Kidson, P; Larsen, FG; Luger, TA; Shear, NH | 1 |
| Anstey, A; Barnes, L; Bolduc, C; Hoffmann, V; Reich, K; Saari, S; Segaert, S; Vaillant, L; van de Kerkhof, PC | 1 |
| Abramovits, W; Colón, LE; Gottschalk, RW; Johnson, LA; Menter, A | 1 |
| Avgerinou, G; Belyayeva, H; Daniel Iii, CR; Gregoriou, S; Katsambas, A; Kontochristopoulos, G; Larios, G; Rigopoulos, D; Stamou, C; Verra, P | 1 |
| Hoffmann, V; Kragballe, K; Nordin, P; Ortonne, JP; Segaert, S; Tan, J | 1 |
| Giovannini, A; Girolomoni, G; Gisondi, P; Rosina, P | 1 |
| Enevold, A; Ganslandt, C; Jemec, GB; van de Kerkhof, PC | 1 |
| Hino, R; Kabashima, R; Kawakami, C; Nakamura, M; Sugita, K; Tokura, Y | 1 |
| Augustin, M; Herberger, K; Kornek, T; Radtke, MA | 1 |
| Appell, M; Bibby, A; Foster, R; Hamilton, T; Lee, M; Mendoza, N; Tyring, S | 1 |
| de Peuter, R; Jansen, JP; Ryttov, J; van de Kerkhof, P | 1 |
| Freeman, K | 1 |
| Affleck, AG; Auland, M; Bottomley, JM; Jackson, P; Ryttov, J | 1 |
| Bottomley, JM; Ryttov, J; Taylor, RS | 1 |
| Chimenti, S; Gniadecki, R; Goldblum, O; Kupper, H; Ortonne, JP; Reich, K; Sprøgel, P; Thaçi, D; Unnebrink, K | 1 |
| McCormack, PL | 2 |
| Murphy, G; Reich, K | 1 |
| Cassano, N; Galluccio, A; Pezza, M; Vena, GA; Vestita, M | 1 |
| Calzavara-Pinton, P; Rossi, MT; Sala, R; Venturini, M | 1 |
| Kircik, LH | 1 |
| Belo, L; Castro, E; Coimbra, S; Figueiredo, A; Oliveira, H; Quintanilha, A; Reis, F; Rocha, S; Rocha-Pereira, P; Santos-Silva, A; Teixeira, F | 1 |
| Bhutani, T; Busse, KL; Koo, J; Patel, T | 1 |
| Enevold, A; Ganslandt, C; Hoffmann, V; Queille-Roussel, C | 1 |
| Newman, MD; Silverberg, NB | 1 |
| Flores, R; Gottlieb, A; Levy, R; Liang, J; Punwani, N; Scherle, P; Shi, J; Williams, W; Yeleswaram, S | 1 |
| Li, W; Man, XY | 1 |
| Fischer, G; Hong, E; Kapila, S | 1 |
| Ayala, F; Cannavò, SP; Chimenti, S; De Pità, O; Girolomoni, G; Peserico, A; Vena, GA | 1 |
| Boyce, BM; Bukhalo, M; Ganslandt, C; Gold, LS; Grekin, S; Kempers, S; Lebwohl, M; Menter, A; Villumsen, J | 1 |
| Hendriks, AG; Hondebrink, E; Seyger, MM; Steenbergen, W; van de Kerkhof, PC; van Hespen, JC | 1 |
| Calvieri, S; Camplone, G; Chimenti, S; D'Agostino, M; De Simone, C; Di Cesare, A; Filosa, G; Frascione, P; Gabellini, M; Lunghi, F; Mazzotta, A; Peris, K; Saraceno, R; Scotto Di Luzio, G; Simonacci, M | 1 |
| Jwa, SW; Kim, BS; Kim, HS; Kim, MB; Ko, HC; Mun, JH; Park, JM; Song, M | 1 |
| Clonier, F; Gupta, AK; Leeder, R; Olesen, M; Silver, S; Taraska, V; Tuppal, R | 1 |
| Ropke, M; Segaert, S | 1 |
| Chimenti, S; Esposito, M; Frangione, V; Grodzińska, A; Kapińska-Mrowiecka, M; Naldi, L; Ortonne, JP | 1 |
| Hol, CW; Lambert, J; Vink, J | 2 |
| Cassano, N; Neri, L; Vena, GA | 1 |
| de Jong, EM; Mul, K; Oostveen, AM; Seyger, MM; van de Kerkhof, PC; van Geel, MJ | 1 |
| Debarre, JM; Gooderham, M; Goodfield, M; Keddy-Grant, J; Kurvits, M; Xu, Z | 1 |
| Clonier, F; Olesen, M; Queille-Roussel, C | 1 |
| Cantrell, W; Elewski, B; Kole, L | 1 |
| Del Rosso, JQ | 1 |
| de Jong, EM; Donders, AR; Oostveen, AM; Seyger, MM; van de Kerkhof, PC | 1 |
| Bachelez, H; de Jong, EM; Gisondi, P; Mrowietz, U; Puig, L; Reich, K; Warren, RB; Zschocke, I | 1 |
| Hendriks, AG; Joosten, I; Keijsers, RR; Koenen, HJ; van de Kerkhof, PC; van Erp, PE | 1 |
| Clark, A; Feldman, SR; Harrison, J; Huang, KE; Sandoval, LF | 1 |
| Bagel, J; Knuckles, ML; Levi, E; Tyring, S | 1 |
| Glick, BP; Touloei, K; Wiener, A | 1 |
| Lacour, JP; Olesen, M; Queille-Roussel, C; Villumsen, J | 1 |
| Annessi, G; Boccaletti, V; Cortelazzi, C; Di Nuzzo, S; Fabrizi, G; Fantini, C; Feliciani, C; Pagliarello, C; Zampetti, A | 1 |
| Cui, P; Facy, P; Gao, T; Ge, M; Gu, J; Hao, F; Kurvits, M; Li, R; Ma, L; Sun, Q; Wang, G; Xu, J; Xu, Z; Yang, H; Yang, Q; Zheng, M | 1 |
| Bagel, J; Bruce, S; Koo, J; Olesen, M; Tyring, S; Villumsen, J; Werschler, WP | 1 |
| Bagel, J; Leonardi, C; Olesen, M; Pariser, D; Stein Gold, L; Xu, Z; Yamauchi, P; Østerdal, ML | 1 |
| Lovato, P; Norsgaard, H; Røpke, MA; Tokura, Y | 1 |
| Stein Gold, LF | 1 |
| Bang, B; Cambazard, F; Griffiths, CE; Kalb, RE; Lowson, D; Paul, C; Stein Gold, L | 1 |
| Koo, J; Lebwohl, M; Menter, A; Rosen, M; Stein Gold, L; Villumsen, J | 1 |
| Bagel, J; Leonardi, C; Moller, A; Osterdal, ML; Pariser, D; Stein Gold, L; Xu, Z; Yamauchi, P | 1 |
| Clark, M; Copley-Merriman, C; Gnanasakthy, A; Zelt, S | 1 |
| Frampton, JE; Kim, ES | 1 |
| Clonier, F; Lacour, JP; Nørremark, K; Queille-Roussel, C; Rosen, M | 1 |
| Gold, LS; Lebwohl, M; Leonardi, C; Menter, A; Møller, A; Paul, C; Reich, K; Warren, RB | 1 |
| Bachelez, H; de Jong, EMGJ; Gisondi, P; Mrowietz, U; Ortland, C; Puig, L; Reich, K; Warren, RB; Zschocke, I | 1 |
| Iizuka, H; Satoh, K; Takagi, A; Takahashi, H | 1 |
| Caldarola, G; De Simone, C; Moretta, G; Peris, K; Poscia, A | 1 |
| Chantzaras, A; Kontodimas, S; Yfantopoulos, J | 1 |
| Asche, CV; Feldman, SR; Kim, M; Lu, M; Zografos, P | 1 |
| Frieder, J; Kivelevitch, D; Menter, A | 1 |
| Bulai Livideanu, C; Kaldate, R; Paul, C; Røpke, M; Snel, A | 1 |
| Goldenberg, G; Hashim, PW; Kircik, LH; Nia, JK; Terrano, D | 1 |
| Ikumi, K; Kubo, R; Morita, A; Muramatsu, S; Nishida, E; Sagawa, Y; Saito, C; Torii, K | 1 |
| Foley, P; Garrett, S; Ryttig, L | 1 |
| Andersen, F; Andersen, KE; Andersen, KH; Svendsen, MT | 1 |
| Anger, T; Gerdes, S; Hutt, HJ; Körber, A; Krakor, M | 1 |
| Cambazard, F; Griffiths, CE; Kalb, RE; Lowson, D; Møller, A; Paul, C; Stein Gold, L | 1 |
| Carretero, G; Puig, L | 1 |
| Adamski, Z; Bowszyc-Dmochowska, M; Dańczak-Pazdrowska, A; Gaura, T; Olek-Hrab, K; Osmola-Mańkowska, A; Polańska, A; Żaba, R | 1 |
| Bagel, J; Nelson, E; Zapata, J | 1 |
| Cantrell, W; Gooding, K; Gorelick, J; Kucera, K; Veverka, KA | 1 |
| Bewley, AP; Calzavara-Pinton, PG; Hansen, JB; Nyeland, ME; Shear, NH; Signorovitch, J | 1 |
| Andersen, SB; Berg, P; Calzavara-Pinton, PG; de la Cueva Dobao, P; Jalili, A; Jensen, KL; Lebwohl, M; Pink, AE; Segaert, S; Stein Gold, L; Thaçi, D | 1 |
| El-Mosallamy, SS; El-Zeany, BA; Hassan, NY; Merey, HA | 1 |
| Duvetorp, A; Engerstedt Mattsson, E; Levin, LÅ; Ryttig, L | 1 |
| Balato, A; Caterino, P; Cirillo, T; Dente, V; Gallo, L; Lodi, G; Megna, M; Mozzillo, R | 1 |
| Berg, P; Calzavara-Pinton, PG; de la Cueva Dobao, P; Jalili, A; Jensen, KL; Pink, AE; Segaert, S; Thaçi, D; Torpet, M | 1 |
| Del Rosso, JQ; Kircik, LH | 1 |
| de Gannes, G; Dutz, J; Han, C; Piesik, P | 1 |
| Fukaya, S; Fukuyasu, A; Hau, CS; Hayashi, K; Ishikawa, T; Kamata, M; Ohnishi, T; Shimizu, T; Tada, Y; Takeoka, S; Tanaka, T | 1 |
| Antunes, J; Balak, DMW; Becla, L; Bewley, A; Calzavara-Pinton, P; Carrascosa, JM; Gregoriou, S; Nyeland, ME; Sawyer, LM; Viola, MG | 1 |
| Gerdes, S; Hubo, M; Velasco, M; Veverka, KA; Wu, JJ | 1 |
| Abramovits, W; Hoejen, MN; Liljedahl, M; Seyger, M; Teng, J | 1 |
| Anger, T; Del Rosso, J; Hansen, B; Kircik, LH; Patel, DS; Veverka, KA | 1 |
| Akiyama, M; Ando, Y; Ohshima, Y; Takama, H; Watanabe, D; Yanagishita, T | 1 |
| Gregoriou, S; Kostakis, P; Panagakis, P; Polydorou, D; Rigopoulos, D; Rompoti, N; Sidiropoulou, P; Tsimpidakis, A; Tsironi, T | 1 |
| Alejo, B; Domínguez, M; Ertekin, SS; Herrero, A; Iglesias, P; Malvehy, J; Martinez, N; Puig, S; Villa-Crespo, L; Yélamos, O; Zamora-Barquero, S | 1 |
| Gold, LS; Hansen, JB; Patel, D; Strober, B; Veverka, KA | 1 |
| Camela, E; Cinelli, E; Fabbrocini, G; Megna, M | 1 |
| Hagiwara, M; Katayama, H; Koda, M; Matsuo, K; Nakagawa, H; Sasaki, H; Takahashi, H; Tanito, K; Uwajima, Y | 1 |
| Ashizawa, S; Hide, M; Takahagi, S; Tanaka, A | 1 |
| Lebwohl, M; Petersen, B | 1 |
| Alonso-Llamazares, J; Cantrell, W; Kircik, L; Koo, J; Moore, A; Stein Gold, L; Teng, J | 1 |
| Gold, LS; Kircik, L; Lacour, JP; Lebwohl, M; Liljedahl, M; Lynde, C; Mørch, MH; Papp, KA; Perrot, JL; Takhar, A; Thaçi, D; Warren, RB; Wollenberg, A | 1 |
| Kircik, LH; Schlesinger, TE; Tanghetti, E | 1 |
| Abramovits, W; Gupta, AK; Teng, JMC; Vincent, KD | 1 |
| Hansen, JB; Nyholm, N; Patel, DS; Swensen, AR; Veverka, KA; Wu, JJ | 1 |
| Ayyagari, R; Glick, B; Guerin, A; Jacobson, A; Joseph, G; Kircik, L; Lin, T | 1 |
| Cao, S; Chen, K; Chen, Y; Cheng, H; Ding, Y; Fang, H; Han, X; He, L; He, Y; Huang, J; Li, M; Li, S; Li, W; Liu, L; Lu, Q; Lu, Y; Pan, W; Wang, J; Yan, G; Zhang, C; Zhang, J; Zheng, M; Zhu, W | 1 |
| Di Guida, A; Fabbrocini, G; Napolitano, M; Patruno, C | 1 |
| Bagel, J; Hetzel, A; Nelson, E; Riley, C | 1 |
| Abd Elazim, NE; Abdel Gaber, RM; El-Deek, HEM; Fathy, E; Kamal, A | 1 |
| Paul, C; Romiti, R; Stein Gold, L | 1 |
| Jalili, A; Yosipovitch, G | 1 |
| Iversen, L; Koo, J; Tada, Y | 1 |
| Armstrong, A; Gerdes, S | 1 |
| Lebwohl, M; Warren, RB | 1 |
| Balogh, EA; Feldman, SR; Heron, CE; Purvis, CG | 1 |
| Dhawan, S; Green, LJ; Praestegaard, M; Selmer, J; Stein Gold, L; Vestbjerg, B | 1 |
| Gold, M; Gooderham, M; Kircik, LH; Lacour, JP; Laws, P; Liljedahl, M; Lynde, C; Mørch, MH; Sondermann, W; Thaçi, D; Warren, RB | 1 |
| Nyholm, N; Petersen, B; Stein Gold, L; Takhar, A; Thoning, H | 1 |
| Asahina, A; Asawanonda, P; Frez, ML; Hyun Kim, D; Imafuku, S; Theng, C; Wang, L; Zhang, JA; Zhao, Y; Zimmo, S | 1 |
| Gooderham, M; Harvima, RJ; Nyholm, N; Stein Gold, L; Thoning, H; Tyring, S | 1 |
| Argenziano, G; Atzori, L; Bianchi, L; Campanati, A; Corazza, M; Damiani, G; De Pità, O; Donini, M; Fargnoli, MC; Feliciani, C; Mazzatenta, C; Mazzotta, A; Offidani, A; Peris, K; Potenza, C; Prignano, F; Stingeni, L; Tiberio, R | 1 |
| Hansen, JB; Kircik, L; Stein Gold, L; Veverka, KA; Yaloumis, M | 1 |
| Augustin, M; Gold, LS; Green, LJ; Pinter, A; Praestegaard, M; Selmer, J | 1 |
| Calzavara-Pinton, P; Dapavo, P; De Simone, C; Fabbrocini, G; Malagoli, P; Martella, A | 1 |
| Bagel, J; Nelson, E | 1 |
| Armstrong, A; Koo, J; Pinter, A; Præstegaard, M; Reich, A; Selmer, J | 1 |
| Kircik, L; Ozyurekoglu, E | 1 |
| Czerwińska, J; Kasprowicz-Furmańczyk, M; Owczarczyk-Saczonek, A; Placek, W | 1 |
| Avey, B; Baker, H; Barker, E; Bewley, A; Galván, J; Green, W; Pi-Blanque, A; Praestegaard, M; Trebbien, P | 1 |
| Arenberger, P; Armstrong, A; Augustin, M; Gold, LS; Iversen, L; Pinter, A; Praestegaard, M; Reich, A | 1 |
| Armstrong, AW; Kircik, L; Lee, K | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
26 review(s) available for betamethasone-17,21-dipropionate and calcitriol
| Article | Year |
|---|---|
Fixed-dose combination therapy for psoriasis.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Dermatologic Agents; Drug Therapy, Combination; Humans; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index | 2004 |
Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Humans; Psoriasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity.
Topics: Administration, Topical; Adult; Aged; Betamethasone; Calcitriol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Randomized Controlled Trials as Topic; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2005 |
[The calcipotriol-betamethasone dipropionate association].
Topics: Administration, Topical; Betamethasone; Calcitriol; Drug Therapy, Combination; Humans; Inflammation; Psoriasis | 2005 |
Calcipotriol/betamethasone dipropionate for the treatment of psoriasis.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cell Differentiation; Cell Proliferation; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Drug Synergism; Humans; Keratinocytes; Psoriasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
[How I treat...topical treatment of plaque type psoriasis by the combination of calcipotriol and betamethasone dipropionate].
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Psoriasis | 2006 |
[Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review].
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Gels; Humans; Incidence; Psoriasis; Scalp Dermatoses; Treatment Outcome | 2010 |
Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris.
Topics: Administration, Topical; Adult; Algorithms; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Treatment Outcome | 2011 |
Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Cost-Benefit Analysis; Drug Combinations; Gels; Humans; Models, Econometric; Psoriasis; Scalp Dermatoses; Scotland; Severity of Illness Index; Treatment Outcome | 2011 |
The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence.
Topics: Administration, Topical; Algorithms; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Drug Combinations; Evidence-Based Practice; Gels; Humans; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Treatment Outcome | 2011 |
Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp.
Topics: Back; Betamethasone; Calcitriol; Clinical Trials as Topic; Dermatologic Agents; Drug Combinations; Extremities; Gels; Humans; Ointments; Psoriasis; Scalp; Thorax; Treatment Outcome | 2011 |
In touch with psoriasis: topical treatments and current guidelines.
Topics: Administration, Topical; Betamethasone; Calcitriol; Dermatologic Agents; Humans; Practice Guidelines as Topic; Psoriasis | 2011 |
Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
Topics: Administration, Cutaneous; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Extremities; Gels; Humans; Ointments; Psoriasis; Scalp; Torso | 2011 |
Solitary morphea profunda following trauma sustained in an automobile accident.
Topics: Accidents, Traffic; Anti-Inflammatory Agents; Antirheumatic Agents; Arm Injuries; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; Middle Aged; Prednisone; Scleroderma, Localized | 2015 |
Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence.
Topics: Administration, Cutaneous; Anthralin; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Nicotinic Acids; Patient Compliance; Pharmaceutical Vehicles; Practice Guidelines as Topic; Psoriasis; Quality of Life; Severity of Illness Index; Tacrolimus; Treatment Outcome; Vitamin D | 2016 |
Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Patient Satisfaction; Quality of Life; Self Report; Skin Diseases; Surveys and Questionnaires | 2017 |
Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque Psoriasis.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Hypothalamo-Hypophyseal System; Pituitary-Adrenal System; Psoriasis; Quality of Life | 2016 |
Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Quality of Life | 2017 |
Update on Topical Treatments for Psoriasis: The Role of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam.
Topics: Administration, Topical; Aerosols; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Humans; Psoriasis | 2019 |
Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE).
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2021 |
Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis | 2020 |
Fixed Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam for Beyond-Mild Psoriasis: A Possible Alternative to Systemic Medication.
Topics: Administration, Cutaneous; Aerosols; Betamethasone; Biological Products; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Humans; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Systematic review and practical guidance on the use of topical calcipotriol and topical calcipotriol with betamethasone dipropionate as long-term therapy for mild-to-moderate plaque psoriasis.
Topics: Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2021 |
A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis.
Topics: Betamethasone; Calcitriol; Clinical Trials, Phase III as Topic; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Long-term maintenance treatment of psoriasis: the role of calcipotriol/betamethasone dipropionate aerosol foam in clinical practice.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2022 |
Real-World Evidence on the Use of Calcipotriene and Betamethasone Dipropionate Aerosol Foam 0.005%/0.064% in the Treatment of Psoriasis: A Review of Investigator-Initiated Studies Around the Globe.
Topics: Aerosols; Calcitriol; Humans; Psoriasis | 2023 |
78 trial(s) available for betamethasone-17,21-dipropionate and calcitriol
| Article | Year |
|---|---|
Calcipotriol: clinical trial versus betamethasone dipropionate + salicylic acid.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Glucocorticoids; Humans; Psoriasis; Salicylates; Salicylic Acid | 1994 |
Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Female; Glucocorticoids; Humans; Male; Middle Aged; Psoriasis; Single-Blind Method; Treatment Outcome | 2000 |
Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study.
Topics: Adult; Aged; Betamethasone; Calcitriol; Cell Cycle; Cell Division; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Flow Cytometry; Humans; Keratin-10; Keratins; Male; Middle Aged; Psoriasis; Skin; Vimentin | 2001 |
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Glucocorticoids; Humans; Male; Middle Aged; Ointments; Psoriasis | 2002 |
A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Ointments; Patient Satisfaction; Psoriasis; Reference Values; Severity of Illness Index; Sweden; Treatment Outcome | 2002 |
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis.
Topics: Adolescent; Betamethasone; Calcitriol; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Pharmaceutical Vehicles; Prospective Studies; Psoriasis; Treatment Outcome | 2003 |
Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Glucocorticoids; Humans; Male; Middle Aged; Ointments; Prospective Studies; Psoriasis; Severity of Illness Index; Treatment Outcome | 2003 |
The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment.
Topics: Adult; Atrophy; Betamethasone; Biopsy, Needle; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Skin; Ultrasonography | 2003 |
Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Canada; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Europe; Female; Humans; Male; Middle Aged; Ointments; Prospective Studies; Psoriasis; Severity of Illness Index | 2004 |
The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial.
Topics: Activities of Daily Living; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Disability Evaluation; Double-Blind Method; Drug Combinations; Female; Health Status Indicators; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Quality of Life; Treatment Outcome | 2004 |
Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial.
Topics: Administration, Topical; Adolescent; Adult; Betamethasone; Calcitriol; Confidence Intervals; Dihydroxycholecalciferols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Odds Ratio; Prospective Studies; Psoriasis; Reference Values; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2004 |
Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of Psoriasis vulgaris.
Topics: Administration, Topical; Adult; Aged; Betamethasone; Calcitriol; Confidence Intervals; Cost-Benefit Analysis; Dihydroxycholecalciferols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Costs; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Ointments; Probability; Psoriasis; Reference Values; Risk Factors; Severity of Illness Index; Treatment Outcome | 2005 |
Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo.
Topics: Administration, Cutaneous; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Ointments; Severity of Illness Index; Treatment Outcome; Vitiligo | 2006 |
Dovobet ointment under occlusion overnight for troublesome scalp psoriasis.
Topics: Administration, Topical; Adolescent; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Scalp Dermatoses; Treatment Outcome | 2006 |
A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris.
Topics: Adult; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Eruptions; Female; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index | 2006 |
Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chi-Square Distribution; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Treatment Outcome | 2006 |
Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment.
Topics: Alefacept; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Etanercept; Female; Humans; Immunoglobulin G; Male; Middle Aged; Ointments; Psoriasis; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Retrospective Studies; Severity of Illness Index | 2006 |
Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Satisfaction; Psoriasis; Safety; Time Factors; Treatment Outcome | 2006 |
Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Patient Compliance; Patient Dropouts; Pilot Projects; Pruritus; Psoriasis; Severity of Illness Index; Time Factors; Treatment Outcome | 2006 |
Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Logistic Models; Male; Maximum Tolerated Dose; Middle Aged; Patient Satisfaction; Probability; Prospective Studies; Psoriasis; Reference Values; Risk Assessment; Scalp Dermatoses; Severity of Illness Index; Treatment Outcome | 2008 |
Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Nail Diseases; Psoriasis; Severity of Illness Index; Single-Blind Method | 2008 |
A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Pharmaceutical Vehicles; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Skin; Treatment Outcome | 2008 |
A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Canada; Denmark; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; France; Germany; Humans; Male; Middle Aged; Ointments; Pharmaceutical Vehicles; Prospective Studies; Psoriasis; Scalp; Severity of Illness Index; Treatment Outcome; United Kingdom | 2008 |
A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Drug Administration Schedule; Drug Combinations; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Treatment Outcome; Young Adult | 2009 |
Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Ointments; Patient Satisfaction; Psoriasis; Quality of Life | 2009 |
Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Nail Diseases; Ointments; Psoriasis | 2009 |
Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Glucocorticoids; Humans; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Young Adult | 2009 |
Microcirculatory modifications of psoriatic lesions during topical therapy.
Topics: Administration, Topical; Adult; Aged; Betamethasone; Calcitriol; Capillaries; Dermatologic Agents; Dermoscopy; Drug Therapy, Combination; Female; Humans; Male; Microcirculation; Microscopic Angioscopy; Middle Aged; Psoriasis; Skin; Treatment Outcome; Young Adult | 2009 |
Significant one week efficacy of a calcipotriol plus betamethasone dipropionate scalp formulation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psoriasis; Scalp; Young Adult | 2011 |
A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Black or African American; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Hispanic or Latino; Humans; Middle Aged; Psoriasis; Scalp Dermatoses; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
Topics: Adalimumab; Administration, Topical; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betamethasone; Calcitriol; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis; Tumor Necrosis Factor-alpha | 2011 |
Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
Topics: Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ointments; Pilot Projects; Psoriasis; Severity of Illness Index; Young Adult | 2012 |
The separate daily application of tacalcitol 4 µg/g ointment and budesonide 0.25 mg/g cream is more effective than the single daily application of a two compound ointment containing calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g.
Topics: Administration, Cutaneous; Adult; Aged; Betamethasone; Budesonide; Calcitriol; Dermatologic Agents; Dihydroxycholecalciferols; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ointments; Pruritus; Psoriasis; Time Factors; Young Adult | 2011 |
Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Betamethasone; Calcitriol; Contraceptives, Oral, Combined; Dermatologic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Male; Middle Aged; Pilot Projects; Psoriasis; Receptors, Tumor Necrosis Factor; Sample Size; Treatment Outcome | 2011 |
Evaluating the efficacy and safety of calcipotriene/betamethasone ointment occluded with a hydrogel patch: a 6-week bilaterally controlled, investigator-blinded trial.
Topics: Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Female; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Male; Middle Aged; Occlusive Dressings; Ointments; Psoriasis; Single-Blind Method; Treatment Outcome | 2011 |
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Janus Kinase 1; Janus Kinase 2; Male; Middle Aged; Nitriles; Pilot Projects; Psoriasis; Pyrazoles; Pyrimidines; Signal Transduction; Treatment Outcome; Young Adult | 2012 |
Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
Topics: Administration, Topical; Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Endpoint Determination; Female; Humans; Immunoglobulin A; Male; Middle Aged; Pharmaceutical Vehicles; Psoriasis; Quality of Life; Skin; Suspensions | 2013 |
Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients.
Topics: Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Gels; Humans; Male; Middle Aged; Psoriasis; Recurrence; Scalp Dermatoses; Young Adult | 2014 |
Efficacy and safety of calcipotriol/betamethasone dipropionate ointment for the treatment of simple onycholysis: an open-label study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Child; Child, Preschool; Dermatologic Agents; Drug Combinations; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Ointments; Onycholysis; Severity of Illness Index; Young Adult | 2013 |
Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial.
Topics: Administration, Cutaneous; Adult; Betamethasone; Calcitriol; Calcium; Creatinine; Dermatologic Agents; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Hypothalamo-Hypophyseal System; Male; Middle Aged; Pituitary-Adrenal System; Psoriasis; Severity of Illness Index; Suspensions; Time Factors | 2013 |
Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial.
Topics: Anti-Inflammatory Agents; Bandages; Betamethasone; Betamethasone Valerate; Calcitriol; Chronic Disease; Dermatologic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Ointments; Prospective Studies; Psoriasis; Single-Blind Method | 2014 |
Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age.
Topics: Administration, Cutaneous; Adolescent; Betamethasone; Calcitriol; Child; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Gels; Humans; Male; Psoriasis; Scalp Dermatoses; Treatment Outcome | 2014 |
Alternative treatment with calcipotriol plus betamethasone dipropionate gel in psoriasis vulgaris using a short-contact approach.
Topics: Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Gels; Humans; Male; Middle Aged; Psoriasis; Treatment Outcome; Young Adult | 2014 |
A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3 mcg/g ointment) when compared to betamethasone diproprionate ointment (64 mg/g) in patients with nail psoriasis.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Double-Blind Method; Female; Humans; Male; Nail Diseases; Ointments; Psoriasis; Treatment Outcome | 2014 |
Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study.
Topics: Administration, Cutaneous; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Gels; Humans; Male; Middle Aged; Patient Preference; Prospective Studies; Psoriasis; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2015 |
Calcipotriene 0.005%--betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Patient Preference; Pilot Projects; Psoriasis; Severity of Illness Index; Suspensions; Treatment Outcome | 2014 |
Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.
Topics: Adult; Aerosols; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Single-Blind Method; Ultrasonography; Young Adult | 2015 |
Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population.
Topics: Administration, Topical; Adult; Asian People; Betamethasone; Calcitriol; China; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Safety; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Solutions; Treatment Outcome | 2016 |
Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
Topics: Adult; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Single-Blind Method; Treatment Outcome | 2016 |
Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Topics: Adolescent; Adult; Aerosols; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Psoriasis; Skin; Treatment Outcome; Young Adult | 2015 |
Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study.
Topics: Adult; Aerosols; Betamethasone; Calcitriol; Female; Gels; Humans; Male; Middle Aged; Psoriasis | 2017 |
Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
Topics: Adolescent; Adult; Aerosols; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Drug Combinations; Drug Compounding; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Statistics as Topic; Treatment Outcome; Young Adult | 2016 |
The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.
Topics: Adult; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Drug Compounding; Female; Health Status; Humans; Male; Psoriasis; Quality of Life | 2016 |
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis.
Topics: Adult; Aerosols; Betamethasone; Betamethasone Valerate; Calcitriol; Dermatologic Agents; Female; Glucocorticoids; Humans; Male; Middle Aged; Psoriasis; Single-Blind Method; Treatment Outcome | 2017 |
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
Topics: Administration, Cutaneous; Adult; Aerosols; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Gels; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome | 2017 |
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP).
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Physician-Patient Relations; Psoriasis; Quality of Life; Treatment Outcome; Young Adult | 2017 |
A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion.
Topics: Administration, Cutaneous; Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index; Skin; Treatment Outcome; Water Loss, Insensible | 2017 |
Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomized controlled trial.
Topics: Administration, Topical; Betamethasone; Calcitriol; Dermatologic Agents; Humans; Medication Adherence; Mobile Applications; Psoriasis; Single-Blind Method | 2018 |
Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.
Topics: Absenteeism; Aerosols; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Gels; Humans; Medication Adherence; Middle Aged; Pruritus; Psoriasis; Quality of Life; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome | 2018 |
Calcipotriol/betamethasone ointment compared to narrow-band UVB in plaque psoriasis: first clinical and ultrasonographic study.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Prospective Studies; Psoriasis; Recurrence; Treatment Outcome; Ultrasonography; Ultraviolet Therapy; Young Adult | 2019 |
A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone; Biological Therapy; Calcitriol; Dermatologic Agents; Drug Compounding; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Treatment Outcome | 2018 |
The Effect of Calcipotriene-Betamethasone Dipropionate Aerosol Foam versus Vehicle on Target Lesions in Moderate Severity Plaque Psoriasis: Focus on Elbows and Knees
Topics: Adult; Aerosols; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Elbow Joint; Female; Humans; Knee Joint; Male; Middle Aged; Pilot Projects; Psoriasis; Severity of Illness Index; Treatment Outcome | 2019 |
Corticosteroid application prior to nickel exposure prevents contact dermatitis in sensitized individuals.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatitis, Allergic Contact; Dermatologic Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Nickel; Patch Tests | 2020 |
Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial.
Topics: Adolescent; Betamethasone; Calcitriol; Child; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2020 |
Effect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis:\
A Post-Hoc Analysis
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis; Young Adult | 2020 |
Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized cl
Topics: Adult; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Humans; Male; Prospective Studies; Psoriasis; Treatment Outcome | 2021 |
PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Body Surface Area; Calcitriol; Data Interpretation, Statistical; Dermatologic Agents; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Psoriasis; Severity of Illness Index; Treatment Outcome | 2020 |
Treating Scalp Psoriasis with Calcipotriene/Betamethasone Dipropionate Fixed-dose Combination Cutaneous Foam: Review of Phase 2 Data
Topics: Administration, Topical; Adolescent; Adult; Aerosols; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Treatment Outcome | 2020 |
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
Topics: Administration, Cutaneous; Adult; Aerosols; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Secondary Prevention; Time Factors; Treatment Outcome; Young Adult | 2021 |
Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aerosols; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pruritus; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome; Visual Analog Scale | 2020 |
Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled
Topics: Adult; Aged; Anti-Inflammatory Agents; Asian People; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Gels; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Scalp Dermatoses; Solutions; Treatment Outcome | 2020 |
Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
Topics: Administration, Cutaneous; Adult; Aerosols; Aged; Betamethasone; Calcitriol; Diarrhea; Drug Combinations; Drug Therapy, Combination; Female; Headache; Humans; Male; Middle Aged; Nausea; Pilot Projects; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome; Young Adult | 2020 |
A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream.
Topics: Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Skin Cream; Treatment Outcome | 2021 |
Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase).
Topics: Administration, Cutaneous; Adult; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome | 2021 |
The Effect on BSA of Proactive Management versus Reactive Management of Psoriasis With Fixed-Dose Cal/BD Foam in the PSO-LONG Study.
Topics: Aerosols; Betamethasone; Body Surface Area; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Humans; Maintenance Chemotherapy; Psoriasis; Quality of Life; Recurrence; Remission Induction; Secondary Prevention; Severity of Illness Index; Treatment Outcome | 2021 |
Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland.
Topics: Aerosols; Betamethasone; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Finland; Humans; Psoriasis; Recurrence; Treatment Outcome | 2022 |
Pooled Analysis Demonstrating Superior Patient- Reported Psoriasis Treatment Outcomes for Calcipotriene/ Betamethasone Dipropionate Cream Versus Suspension/Gel.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Patient Reported Outcome Measures; Psoriasis; Quality of Life; Treatment Outcome | 2022 |
Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Emollients; Humans; Psoriasis; Treatment Outcome | 2023 |
75 other study(ies) available for betamethasone-17,21-dipropionate and calcitriol
| Article | Year |
|---|---|
In vitro compatibility of tazarotene with other topical treatments of psoriasis.
Topics: Administration, Topical; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Drug Evaluation, Preclinical; Drug Incompatibility; Fluocinonide; In Vitro Techniques; Mometasone Furoate; Nicotinic Acids; Pregnadienediols; Psoriasis | 2000 |
[New ointment with vitamin D derivative and corticoid. Psoriasis therapy combined].
Topics: Betamethasone; Calcitriol; Clinical Trials as Topic; Dermatologic Agents; Drug Combinations; Humans; Ointments; Psoriasis | 2003 |
Once daily application of a combination of calcipotriol and betamethasone dipropionate (Dovobet, Daivobet) for the treatment of psoriasis.
Topics: Adult; Betamethasone; Calcitriol; Confidence Intervals; Data Interpretation, Statistical; Dermatologic Agents; Double-Blind Method; Drug Combinations; Humans; Multicenter Studies as Topic; Patient Compliance; Prospective Studies; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors | 2003 |
Bioavailability of betamethasone dipropionate when combined with calcipotriol.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Biological Availability; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Interactions; Humans; Male; Middle Aged; Pilot Projects; Psoriasis | 2004 |
Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle.
Topics: Administration, Topical; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Denmark; Drug Combinations; Drug Compounding; Drug Design; Humans; Ointments; Permeability; Pharmaceutical Vehicles; Skin; Solubility | 2004 |
Once daily vs. twice daily applications of topical treatments in psoriasis.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Humans; Psoriasis | 2005 |
Treatment of guttate psoriasis with a new two-compound product containing calcipotriol and betamethasone dipropionate.
Topics: Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Ointments; Psoriasis | 2005 |
Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis.
Topics: Adult; Betamethasone; Calcitriol; Clinical Trials, Phase III as Topic; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Psoriasis; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2006 |
Generalized pustular psoriasis complicated by acute respiratory distress syndrome.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Male; Middle Aged; Psoriasis; Respiratory Distress Syndrome | 2006 |
Treatment of scalp psoriasis with betamethasone dipropionate and calcipotriol two-compound product.
Topics: Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Treatment Outcome | 2007 |
Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity?
Topics: Anti-Inflammatory Agents; Betamethasone; Biological Products; Calcitriol; Dermatologic Agents; Drug Administration Routes; Humans; Psoriasis; Severity of Illness Index; Skin Diseases; Treatment Outcome | 2007 |
Pulsed dye laser versus treatment with calcipotriol/betamethasone dipropionate for localized refractory plaque psoriasis: effects on T-cell infiltration, epidermal proliferation and keratinization.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antigens, CD; Betamethasone; Biopsy; Calcitriol; Cell Proliferation; Dermatologic Agents; Drug Therapy, Combination; Epidermis; Female; Humans; Keratinocytes; Low-Level Light Therapy; Male; Ointments; Psoriasis; Skin; T-Lymphocytes; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; Treatment Outcome | 2007 |
Advances in first-line topical therapies: the role of a 2-compound ointment for psoriasis vulgaris.
Topics: Administration, Topical; Adrenal Cortex Hormones; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Humans; Ointments; Psoriasis | 2007 |
First case series on the use of calcipotriol-betamethasone dipropionate for morphoea.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Female; Humans; Male; Middle Aged; Scleroderma, Localized; Treatment Outcome | 2007 |
Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Quality-Adjusted Life Years; Scotland; State Medicine; Treatment Outcome | 2007 |
Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol).
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Gels; Humans; Psoriasis; Scalp Dermatoses; Treatment Outcome | 2009 |
Circulating Th17 cell fluctuation in psoriatic patients treated with topical calcipotriol and betamethasone butyrate propionate.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Psoriasis; Th17 Cells; Treatment Outcome | 2011 |
The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis - an introduction.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Drug Combinations; Humans; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Treatment Outcome | 2011 |
Erythroid disturbances before and after treatment of Portuguese psoriasis vulgaris patients: a cross-sectional and longitudinal study.
Topics: Adult; Betamethasone; Calcitriol; Cross-Sectional Studies; Dermatologic Agents; Erythroid Cells; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neutrophil Activation; Oxidative Stress; Photochemotherapy; Psoriasis; Ultraviolet Therapy | 2012 |
Use of a psoriasis plaque test in the development of a gel formulation of calcipotriol and betamethasone dipropionate for scalp psoriasis.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Dermatologic Agents; Drug Combinations; Drug Compounding; Female; Gels; Humans; Male; Ointments; Psoriasis; Scalp; Treatment Outcome; Young Adult | 2013 |
Once-daily application of calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for repigmentation of facial vitiligo.
Topics: Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Child; Child, Preschool; Dermatologic Agents; Drug Combinations; Face; Female; Humans; Male; Middle Aged; Ointments; Treatment Outcome; Vitiligo | 2011 |
Linear psoriasis.
Topics: Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Diagnosis, Differential; Drug Combinations; Humans; Male; Psoriasis; Skin Diseases | 2012 |
A comparative study of childhood psoriasis and atopic dermatitis and greater understanding of the overlapping condition, psoriasis-dermatitis.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Child; Child, Preschool; Dermatitis, Atopic; Dermatologic Agents; Diagnosis, Differential; Female; Humans; Infant; Male; Psoriasis; Ultraviolet Therapy | 2012 |
Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Gels; Humans; Psoriasis; Quality of Life; Scalp Dermatoses; Time Factors | 2012 |
Whole field laser Doppler imaging of the microcirculation in psoriasis and clinically unaffected skin.
Topics: Aged; Betamethasone; Calcitriol; Dermatologic Agents; Female; Heart Rate; Humans; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Pilot Projects; Psoriasis; Skin; Treatment Outcome | 2014 |
The biological rationale for use of vitamin d analogs in combination with corticosteroids for the topical treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Animals; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Glucocorticoids; Humans; Psoriasis; Vitamin D | 2013 |
Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study.
Topics: Adolescent; Adult; Aged; Betamethasone; Calcitriol; Drug Administration Schedule; Female; Gels; Humans; Male; Middle Aged; Ointments; Patient Satisfaction; Prospective Studies; Psoriasis; Quality of Life; Young Adult | 2014 |
Prescription size and adherence in the management of psoriasis: is the more, the better?
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Attitude of Health Personnel; Betamethasone; Calcitriol; Clobetasol; Dihydroxycholecalciferols; Dose-Response Relationship, Drug; Drug Prescriptions; Gels; Humans; Immunosuppressive Agents; Medication Adherence; Practice Patterns, Physicians'; Psoriasis | 2014 |
Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort.
Topics: Adolescent; Betamethasone; Calcitriol; Child; Child, Preschool; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Ointments; Prospective Studies; Psoriasis; Quality of Life; Treatment Outcome | 2014 |
Calcipotriene-betamethasone dipropionate topical suspension in the management of psoriasis: a status report on available data with an overview of practical clinical application.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Dermatologic Agents; Dermatology; Drug Combinations; Evidence-Based Medicine; Humans; Psoriasis; Suspensions; Treatment Outcome | 2014 |
Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children's quality of life in daily practice.
Topics: Administration, Cutaneous; Adolescent; Betamethasone; Calcitriol; Child; Child, Preschool; Drug Combinations; Female; Humans; Male; Prospective Studies; Psoriasis; Quality of Life; Scalp Dermatoses; Severity of Illness Index | 2015 |
Balance of Treg versus T-effector cells during systemic treatment with adalimumab and topical treatment with calcipotriol-betamethasone dipropionate ointment.
Topics: Adalimumab; Administration, Topical; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betamethasone; Biopsy; Calcitriol; CD4-Positive T-Lymphocytes; Female; Forkhead Transcription Factors; Humans; Immunohistochemistry; Inflammation; Male; Middle Aged; Ointments; Psoriasis; Skin; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tumor Necrosis Factor-alpha | 2015 |
Real-life treatment profile of calcipotriene and betamethasone dipropionate topical suspension in patients with psoriasis vulgaris.
Topics: Administration, Cutaneous; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Pruritus; Psoriasis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Suspensions; Treatment Outcome | 2014 |
Calcipotriol/betamethasone dipropionate ointment compared with tacrolimus ointment for the treatment of erosive pustular dermatosis of the scalp: a split-lesion comparison.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Immunosuppressive Agents; Ointments; Scalp Dermatoses; Tacrolimus | 2015 |
Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Child; Dermatologic Agents; Drug Combinations; Female; Gels; Humans; Male; Medication Adherence; Middle Aged; Ointments; Patient Satisfaction; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Time Factors; Young Adult | 2015 |
Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis.
Topics: Adrenal Cortex Hormones; Betamethasone; Calcitriol; Cell Communication; Cell Differentiation; Cells, Cultured; Cytokines; Drug Therapy, Combination; Gene Expression Regulation; Humans; Immunologic Factors; Inflammation Mediators; Keratinocytes; Langerhans Cells; Phenotype; Psoriasis; Receptors, Calcitriol; Signal Transduction; Th17 Cells; Tissue Culture Techniques | 2016 |
Economic burden of psoriatic patients in Japan: Analysis from a single outpatient clinic.
Topics: Administration, Cutaneous; Administration, Topical; Adult; Aged; Ambulatory Care Facilities; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Betamethasone; Biological Products; Calcitriol; Cost of Illness; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Female; Glucocorticoids; Humans; Japan; Male; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Role of personalized medication training in improving efficacy and adherence to a topical therapy in psoriatic patients.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Humans; Linear Models; Male; Middle Aged; Patient Compliance; Patient Education as Topic; Patient Satisfaction; Psoriasis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Young Adult | 2017 |
Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis.
Topics: Adolescent; Adult; Aged; Anxiety; Betamethasone; Calcitriol; Depression; Dermatologic Agents; Female; Health Status; Health Surveys; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Psoriasis; Psychometrics; Quality of Life; Young Adult | 2017 |
Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs.
Topics: Betamethasone; Biological Products; Budgets; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Models, Econometric; Psoriasis; Severity of Illness Index; United States | 2017 |
Changes in interleukin-17A, macrophage-derived chemokine and adiponectin following treatment of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam: results from the PSO-ABLE study.
Topics: Adiponectin; Administration, Cutaneous; Aerosols; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemokine CCL22; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Interleukin-17; Male; Middle Aged; Psoriasis; Treatment Outcome | 2018 |
Low incidence of hypercalcemia following combined calcipotriol hydrate/betamethasone dipropionate ointment treatment in Japanese patients with severe psoriasis vulgaris.
Topics: Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Calcium; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Incidence; Japan; Male; Middle Aged; Ointments; Psoriasis; Severity of Illness Index; Treatment Outcome | 2018 |
A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis.
Topics: Aerosols; Betamethasone; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Humans; Ointments; Psoriasis; Quality-Adjusted Life Years | 2018 |
Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions.
Topics: Adult; Aerosols; Aged; Anti-Inflammatory Agents; Betamethasone; Body Surface Area; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Severity of Illness Index; Treatment Outcome | 2017 |
Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Patient Satisfaction; Psoriasis; Self Report; Treatment Outcome; Young Adult | 2018 |
Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Topics: Acitretin; Administration, Cutaneous; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Esters; Female; Fumarates; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Thalidomide; Treatment Outcome | 2019 |
Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
Topics: Administration, Cutaneous; Adult; Aged; Betamethasone; Calcitriol; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Dyssomnias; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pruritus; Psoriasis; Quality of Life; Randomized Controlled Trials as Topic; Single-Blind Method; Visual Analog Scale | 2019 |
Validated Chromatographic Methods for Simultaneous Determination of Calcipotriol Monohydrate and Betamethasone Dipropionate in the Presence of Two Dosage Form Additives.
Topics: Betamethasone; Calcitriol; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Limit of Detection; Linear Models; Ointments; Reproducibility of Results | 2019 |
A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden.
Topics: Administration, Cutaneous; Aerosols; Betamethasone; Calcitriol; Clinical Decision-Making; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Dermatologic Agents; Disease Progression; Drug Compounding; Drug Costs; Glucocorticoids; Humans; Models, Economic; Office Visits; Ointments; Phototherapy; Psoriasis; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sweden; Time Factors; Treatment Outcome | 2019 |
Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation.
Topics: Administration, Topical; Adult; Aerosols; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Hand; Humans; Male; Middle Aged; Pain; Pain Measurement; Pain Threshold; Prospective Studies; Psoriasis; Severity of Illness Index; Young Adult | 2019 |
Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Patient Compliance; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2019 |
Calcipotriol and betamethasone dipropionate exhibit different immunomodulatory effects on imiquimod-induced murine psoriasiform dermatitis.
Topics: Administration, Cutaneous; Animals; Betamethasone; Calcitriol; Cytokines; Dermatologic Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Gene Expression Regulation; Glucocorticoids; Humans; Imiquimod; Mice; Ointments; Psoriasis; Skin; Th1 Cells; Th17 Cells | 2020 |
Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2021 |
Two cases of refractory nail psoriasis successfully treated with calcipotriol plus betamethasone dipropionate gel.
Topics: Administration, Oral; Aged; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Drug Combinations; Drug Resistance; Female; Gels; Humans; Male; Middle Aged; Nail Diseases; Ointments; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Treatment of nail psoriasis with calcipotriol/betamethasone dipropionate foam versus pulse dye laser: an unblinded, intra-patient, left-to-right prospective study.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Lasers, Dye; Prospective Studies; Psoriasis; Treatment Outcome | 2020 |
Patient satisfaction and efficacy of calcipotriol plus betamethasone dipropionate gel in plaque psoriasis patients with poor adherence.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Patient Satisfaction; Psoriasis; Treatment Outcome | 2020 |
Grover's disease successfully treated with calcipotriene/betamethasone dipropionate ointment.
Topics: Acantholysis; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Ichthyosis; Ointments; Psoriasis | 2020 |
Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam for Plaque Psoriasis in Adolescents Aged 12-17 Years.
Topics: Administration, Cutaneous; Adolescent; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Psoriasis; Treatment Outcome | 2020 |
Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matchi
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adju
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Hailey-Hailey disease treated successfully with calcipotriol plus betamethasone dipropionate aerosol foam: A case report.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Pemphigus, Benign Familial; Psoriasis; Treatment Outcome | 2021 |
Efficacy of topical calcipotriol betamethasone dipropionate as a new adjuvant therapy to follicular unit extraction technique in treatment of stable vitiligo: clinical, dermoscopic and immunohistological study.
Topics: Betamethasone; Calcitriol; Combined Modality Therapy; Humans; Treatment Outcome; Ultraviolet Therapy; Vitiligo | 2021 |
Efficacy and safety of fixed-dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Hypothalamo-Hypophyseal System; Pituitary-Adrenal System; Psoriasis; Treatment Outcome | 2021 |
Fixed-dose combination calcipotriol/betamethasone dipropionate foam provides a rapid onset of action, effective itch relief and improves patient quality of life.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Quality of Life; Treatment Outcome | 2021 |
Early efficacy and safety data with fixed-dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Hypothalamo-Hypophyseal System; Pituitary-Adrenal System; Psoriasis; Treatment Outcome | 2021 |
Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost-effective.
Topics: Betamethasone; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Germany; Humans; Patient Satisfaction; Psoriasis; Quality of Life; Spain; Treatment Outcome | 2021 |
Editorial: fixed-dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Ointments; Psoriasis; Treatment Outcome | 2021 |
Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation.
Topics: Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Evaluation; Humans; Psoriasis; Treatment Outcome | 2021 |
Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study.
Topics: Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Psoriasis; Treatment Outcome | 2021 |
Calcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Dosage Forms; Drug Combinations; Humans; Prospective Studies; Psoriasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Middle Aged; Prospective Studies; Psoriasis; Treatment Outcome | 2022 |
The Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Pilot Projects; Psoriasis; Thalidomide; Treatment Outcome | 2022 |
The Effect of the Long-Term Calcipotriol/Betamethasone Dipropionate Local Therapy on Tissue Resident Memory Cells Markers in Psoriatic Eruptions.
Topics: Betamethasone; Calcitriol; Humans; Immunologic Memory; Interleukin-17; Psoriasis; Recurrence | 2022 |
An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2022 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |